Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
12.4 USD | +4.47% | +10.59% | +43.26% |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 589M |
---|---|---|---|---|---|
Net income 2024 * | -124M | Net income 2025 * | -160M | EV / Sales 2024 * | - |
Net cash position 2024 * | 86.23M | Net cash position 2025 * | 102M | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-4.63
x | P/E ratio 2025 * |
-4.05
x | Employees | 28 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 86.63% |
Latest transcript on Mineralys Therapeutics, Inc.
1 day | +3.92% | ||
1 week | +10.77% | ||
Current month | -4.42% | ||
1 month | -5.30% | ||
3 months | +12.80% | ||
6 months | +52.91% | ||
Current year | +43.49% |
Managers | Title | Age | Since |
---|---|---|---|
Jon Congleton
CEO | Chief Executive Officer | 60 | 20-10-31 |
Adam Levy
DFI | Director of Finance/CFO | 46 | 22-02-28 |
Jessica Ibbitson
CTO | Chief Tech/Sci/R&D Officer | - | 21-02-28 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 56 | 21-01-31 | |
Glenn Sblendorio
BRD | Director/Board Member | 68 | 23-09-12 |
Director/Board Member | 58 | 21-01-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 34 M€ | +2.67% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-29 | 12.28 | +3.45% | 31 099 |
24-04-26 | 11.87 | +7.52% | 65,808 |
24-04-25 | 11.04 | -2.82% | 52,730 |
24-04-24 | 11.36 | -0.61% | 53,781 |
24-04-23 | 11.43 | +2.60% | 139,605 |
Delayed Quote Nasdaq, April 29, 2024 at 12:55 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+43.49% | 589M | |
+2.56% | 42.75B | |
+47.70% | 41.61B | |
+12.12% | 41.34B | |
-8.83% | 26.59B | |
+8.21% | 25.49B | |
-22.68% | 18.12B | |
+30.86% | 12.24B | |
-1.63% | 11.76B | |
+9.16% | 11B |
- Stock Market
- Equities
- MLYS Stock